Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | CA3 | P07451 | 1/20 | 0.69 |
| ▸ | CA4 | P22748 | 1/20 | 0.69 |
| ▸ | CA6 | P23280 | 1/20 | 0.69 |
| ▸ | CA5A | P35218 | 1/20 | 0.69 |
| ▸ | CA7 | P43166 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.69 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880935 | 1.00 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3789749 | 1.00 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL15723483 | 0.88 | LMNA (0.56) | LMNACA12CA1CA2CA3 | |
| SCHEMBL21313417 | 0.87 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1878246 | 0.87 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8353244 | 0.87 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13911898 | 0.86 | LMNA (0.71) | LMNACA12CA1CA2CA3 | |
| SCHEMBL4445759 | 0.83 | LMNA (0.63) | LMNACA12CA1CA2CA3 | |
| SCHEMBL14610554 | 0.82 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL5101967 | 0.82 | LMNA (0.50) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114409586-A | Preparation method of levetiracetam | 山东诚汇双达药业有限公司 | 2022-04-29 | — | — | CN | claimed |
| CN-115734964-B | Levetiracetam Process for the preparation of intermediates | 浙江华海药业股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-118748991-A | Purified levetiracetam Process for preparing tam intermediates | 浙江华海药业股份有限公司 | 2024-10-08 | — | — | CN | disclosed |
| CN-116836099-A | Method for recovering (R/S) -alpha-ethyl-2-oxo-1-pyrrolidine acetic acid from wastewater | 浙江华海药业股份有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116655513-A | Preparation method of high-purity levetiracetam | 重庆圣华曦药业股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-110799494-B | Method for preparing levetiracetam without solvent | 浙江华海药业股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-110799495-B | Synthesis method of levetiracetam | 浙江华海药业股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-114409586-A | Preparation method of levetiracetam | 山东诚汇双达药业有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20190152908-A1 | PROCESSES TO PRODUCE BRIVARACETAM | ESTEVE QUIMlCA S.A. (ES) | 2019-05-23 | — | — | US | disclosed |
| CN-104059010-A | Preparation method of 2-(2-oxopyrrolidine-1-yl)-butyrate | ZHEJIANG HUAHAI PHARM CO LTD | 2014-09-24 | — | — | CN | disclosed |
| EP-1806339-A1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB, S.A. (BE) | 2007-07-11 | — | — | EP | disclosed |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | ATES CELAL | 2007-06-21 | — | — | US | disclosed |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | ATES CELAL | 2007-06-21 | — | — | US | disclosed |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | ATES CELAL | 2007-06-21 | — | — | US | disclosed |
| US-20060258734-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2006-11-16 | — | — | US | disclosed |
| US-7122682-B2 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | UCB, S.A. (BE) | 2006-10-17 | — | — | US | disclosed |
| US-20040204476-A1 | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2004-10-14 | — | — | US | disclosed |
| EP-1419144-A2 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB, S.A. (BE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003014080-A2 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB, S.A. (BE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003014080-A2 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB, S.A. (BE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152908-A1 | PROCESSES TO PRODUCE BRIVARACETAM | BLVRB, CYP3A4, POR | LMNA 3886/4885CA12 2526/4885CA1 4013/4885 |
| US-20040204476-A1 | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues | CYP2C19, CYP2C9, TPMT | LMNA 3589/4885CA12 2116/4885CA1 1011/4885 |
| US-20060258734-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | TPMT, CYP2C9, OTC | LMNA 2489/4885CA12 2370/4885CA1 1525/4885 |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | CYP2D6, OTC, CYP2B6 | LMNA 2327/4885CA12 2417/4885CA1 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.